USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 4 mg in 4 ml - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)] . risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no ava

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 4 mg in 4 ml - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)] . risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no ava

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

farmalider s.a. - topotecan hidrocloruro - polvo para concentrado para soluciÓn para perfusiÓn - 1 mg - topotecan hidrocloruro 1 mg - topotecán

USA - engelsk - NLM (National Library of Medicine)

bedford laboratories - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 4 mg in 4 ml - topotecan hydrochloride for injection is indicated for the treatment of:  - small cell lung cancer sensitive disease after failure of first-line chemotherapy. in clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy [see clinical studies (14) ].  - topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.  topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions (e.g., anaphylactoid reactions) to topotecan or to any of its ingredients. topotecan hydrochloride for injection should not be used in patients with severe bone marrow depression.  pregnancy category d [see

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

accord healthcare s.l.u., spain edificio este planta 6, world trade center, 08039 barcelona +34 93 301 0064 - topotecan hydrochloride - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 1mg/ml - topotecan hydrochloride 1,086mg - topotecan

Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

accord healthcare s.l.u (0000009808) moll de barcelona, edifici est s/n, planta 6, barcelona, 08039 - topotecan hydrochloride - concentrate for solution for infusion - 1mg/ml - topotecan hydrochloride (8000001521) 1,0865mg - topotecan

Canada - engelsk - Health Canada

pfizer canada ulc - topotecan (topotecan hydrochloride) - solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

Canada - engelsk - Health Canada

accord healthcare inc - topotecan (topotecan hydrochloride) - solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride 1 mg in 1 ml - topotecan injection is indicated for the treatment of: - small cell lung cancer sensitive disease after failure of first-line chemotherapy. in clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy [see clinical studies (14) ] . topotecan injection in combination with cisplatin is indicated for the treatment of: - stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. topotecan injection is contraindicated in patients who have a history of severe hypersensitivity reactions (e.g., anaphylactoid reactions) to topotecan or to any of its ingredients. topotecan injection should not be used in patients with severe bone marrow depression. pregnancy category d [see warnings and precautions (5.4) ]. topotecan injection can cause fetal harm

Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - topotecanhydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentraat voor oplossing voor infusie - 1 mg/ml - topotecanhydrochloride - topotecan